Abstract
Proton pump inhibitors (PPIs) are recommended in patients with prior upper gastrointestinal bleeding and considered appropriate in patients with multiple other risk factors who require dual antiplatelet treatment (DAPT). During the past few years, however, concerns have been raised about the potential for PPIs, especially omeprazole, to decrease the efficacy of clopidogrel, and both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued warnings regarding the concomitant use of these medications. A review of the literature revealed that the pharmacodynamic studies support an interaction, whereas the clinical evidence, which is mainly based on nonrandomized, observational studies and secondary analyses of randomized trials, is conflicting. We conclude that PPIs should be prescribed together with DAPT for patients in whom they are recommended according to the guidelines and for patients with other indications. With respect to omeprazole, current evidence does not allow clear recommendations to be provided.
Keywords: Proton pump inhibitors, omeprazole, clopidogrel, CYP2C19, drug interactions.
Current Vascular Pharmacology
Title:The Clopidogrel-PPI Interaction: An Updated Mini-Review
Volume: 12 Issue: 5
Author(s): Jacob Juel, Manan Pareek and Svend Eggert Jensen
Affiliation:
Keywords: Proton pump inhibitors, omeprazole, clopidogrel, CYP2C19, drug interactions.
Abstract: Proton pump inhibitors (PPIs) are recommended in patients with prior upper gastrointestinal bleeding and considered appropriate in patients with multiple other risk factors who require dual antiplatelet treatment (DAPT). During the past few years, however, concerns have been raised about the potential for PPIs, especially omeprazole, to decrease the efficacy of clopidogrel, and both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued warnings regarding the concomitant use of these medications. A review of the literature revealed that the pharmacodynamic studies support an interaction, whereas the clinical evidence, which is mainly based on nonrandomized, observational studies and secondary analyses of randomized trials, is conflicting. We conclude that PPIs should be prescribed together with DAPT for patients in whom they are recommended according to the guidelines and for patients with other indications. With respect to omeprazole, current evidence does not allow clear recommendations to be provided.
Export Options
About this article
Cite this article as:
Juel Jacob, Pareek Manan and Jensen Eggert Svend, The Clopidogrel-PPI Interaction: An Updated Mini-Review, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/157016111205140926161509
DOI https://dx.doi.org/10.2174/157016111205140926161509 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Synthetic Strategies for the Construction of δ-Carbolines: A Chemical Ladder in Search of Novel Drugs
Current Organic Synthesis Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Small Animal Computed Tomography Imaging
Current Medical Imaging The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Editorial [Hot Topic:Neurodegenerative Disorders: From Molecules to Man (Part 1) (Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito)]
CNS & Neurological Disorders - Drug Targets The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy
Current HIV Research Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Quantitative Analysis of UGT2B28 mRNA Expression by Real-Time RT-PCR and Application to Human Tissue Distribution Study
Drug Metabolism Letters The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Regenerative Therapies for Improving Myocardial Perfusion in Patients with Cardiovascular Disease: Failure to Meet Expectations but Optimism for the Future
Current Vascular Pharmacology Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Mitochondrial Functionality and Chemical Compound Action on Sperm Function
Current Medicinal Chemistry Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)